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Abstract
One of the notable advances in modern day medicine is organ transplantation. None more so than the heart. A complex 
interaction between physiology, surgery and immunology that spanned decades, involving the hard work of many 
pioneers in their fields. We revisit the contributions of the pioneers as well as marvel at the paradigm shifts in medicine 
that have made heart transplantation safe and reproducible with in excess of 3000 transplants done yearly today.
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ORGAN TRANSPLANTATION AND ANCIENT HISTORY
Organ transplantation is arguably one of the greatest feats of modern medicine of the past century. Initially 
stemming from historical experimentation, it has become a mainstay of treatment for many chronic condi-
tions and continues to do so in spite of improvements in device technology. Organ donation however under-
went several challenges initially with cultural acceptance, ethics and legality, and political pressure. It has 
since evolved with the merging of improvements in the donation-allocation-procurement process, advances 
in technology, refinement of surgical technique, scientific breakthroughs in organ preservation, cognitive 
and methodical improvements in immunology and immunosuppression alongside expertise in managing 
adherent complications of organ transplantation.
In ancient civilisations, the practice of removal of organ/tissues for a multitude of reasons (beautification or 
therapeutic) was initiated. Hindu texts from 3 millennia ago provide detailed accounts of skin grafting from 
fatty regions (buttocks) or protrusions (chin) for reconstruction of mutilated noses incurred during wars 
or punishments[1].
One of the earliest records of organ transplantation, Bian Que, a reported clairvoyant during Han Dynasty 
in Ancient China reportedly performed an exchange of hearts. He felt that the attainment of balance was 
possible by exchanging organs between men of “strong will” but “weak spirit” with that of one with op-
posite traits by intoxicating a “patient” with fortified wine prior to “cutting their breasts removing their 
hearts and applying numinous medicine”[2].
The New Testament describes several cases of auto-transplantation by today’s definition; Jesus of Nazareth 
reattached the ear of a servant after it had been cut by Simon Peter’s sword. It also describes how Saint 
Mark re-implanted an amputated hand of a soldier[3]. Archaeological records have revealed that in the 
Bronze age, the term “trephination” was first revealed whereby bone segments were temporarily removed 
to decompress brain swelling[4].
Jacopoda Varagine (348 AD) described the “miracle of the black leg” where a gangrenous leg of Justinian 
(Roman deacon) was replaced with that of a dead Ethiopian man[5].
In 1688, Job van Meeneren successfully grafted a segment of bone from the skull of a dog to a defect in a 
human patient’s cranium[6]. A Russian aristocrat had a fragment of canine skull tissue inserted during a 
repair after an injury. He had it explanted due to threats of excommunication from the church[6]. Such ac-
counts of events highlighted the initial inquisitiveness with the concept of transplantation.
THE PRE-TRANSPLANT ERA
Although organ transplantation had not taken place yet, the early 20th century witnessed the first skin and 
corneal transplants. The initial work behind corneal transplant is attributed to Franz Reisinger who experi-
mented with “keratoplasty” in 1818[7]. Twenty years later, Samuel Bigger performed the first successful cor-
neal transplant in a gazelle. The first attempted corneal xenotransplantation on a human was performed in 
1838 was unsuccessful. Improvements in antisepsis, anaesthesiology and surgical technique played a pivotal 
role, alongside ongoing animal experimentation. This subsequently led to the first successful human corneal 
transplant in 1905 by a Eduard Zirm (1887-1948) in Olmutz near Prague[7]. The first successfully grafted tis-
sue however was performed by Jacques-Louis Reverdin, who transplanted small detached skin grafts onto 
a wound and noted hastened granulating of wounds on 8th December 1869[8]. Solid organ transplantation 
would follow a similar path with years of experimentation, before successful results were noted.
French president Marie François Sadi Carnot died from severed portal vein in 1894. This had a profound 
effect on a young surgeon, Alexis Carrell[9]. He mastered vascular anastomotic suturing methods and intro-
duced smaller needles. Carrel coated his needles, instruments and thread with petroleum jelly to reduce the 
thrombogenicity of the foreign material. He also perfected the concept of eversion thereby allowing blood 
within the vessels continuous endothelial contact. He also revolutionised antisepsis in surgery and pioneered 
methods of extracorporeal tissue preservation, by using salt solution at freezing point[10].
In 1902, he successfully performed the first heterotopic kidney transplant by inserting a dog’s kidney into its 
own neck. He noted that the kidney began producing urine immediately[9]. He later successfully transplant-
ed organs, including kidneys, ovaries and thyroid glands between different dogs. In 1912, he became the 
first surgeon to win a Nobel Prize “in recognition of his work on vascular sutures and the transplantation of 
blood vessels and organs”[11].
To prevent blood clotting Carrel coated his needles, instruments and thread with paraffin jelly and he used 
an everting technique, rolling back the cut vessel ends like cuffs and then stitching the turned-back ends 
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together to ensure that the blood would keep contact with the smooth inside of the vessel (endothelium). 
This and the use of strict asepsis to avoid infection allowed him to develop the techniques further by mov-
ing hearts, kidneys and spleens during experiments in dogs and also allowed other groups to begin experi-
mentation in animal models of transplantation. Carrell famously noted that despite success in the technical 
aspects of transplantation, there were consistent hostile host responses to the foreign allografts especially 
during xenotransplantation[12].
“Should an organ, extirpated from an animal and replanted into its owner by a certain technique, continue 
to functionate normally, and should it cease to functionate normally when transplanted into another ani-
mal by the same technique, the physiologic disturbance could not be considered as brought about by the 
organ but would be due to the influence of the host, that is, the biological factors”.
Despite Carrell’s observations, between 1905-1910, several surgical peers such as M Princeteau, Mathieu 
Jaboulay and Ernst Unger in this era attempted xenotransplantation of rabbit, pig and macaque kidneys to 
humans with disastrous results[13].
PRE-IMMUNOSUPPRESSION ERA
Leo Loeb first noted that the strength and timing of rejection in skin homografts on rodents was potentially 
caused by genetic disparity between donor and recipient and highlighted the involvement of lymphocytes in 
the 1930s[14]. He theorised that this genetic disparity did not occur in identical twins thus they would accept 
exchanged skin grafts. Unfortunately, his findings were ridiculed due to his inbreeding of mice. Contempo-
raries such as Peter Medawar dismissed the importance of lymphocytes and adopted the humoral theory of 
rejection[14]. The ensuing two decades were fraught with failed attempts of kidney transplantation in both 
human and animal models by Voronoy (1937), Simonsen (1953) and Dempster (1953) who even used radia-
tion in organ transplant recipients[15]. Medawar’s renewed interest in transplant rejection brought him to the 
Burns Unit at Glasgow Royal Infirmary (Gibson and Medawar, 1943) with Thomas Gibson. He remained 
convinced that skin grafts in burn victims failed because of humoral rather than cellular immunity[16]. His 
work with Rupert Billingham and Hugh Donald revealed that even fraternal twin cows accepted skin grafts, 
not just identical twin cows[17]. Across the Atlantic, Ray Owen at the University of Wisconsin noted a hybrid 
of blood cell types in fraternal twins. He concluded that there was persistence of chimerism from the in-
trauterine transfer of stem cells which was probably responsible for this[14]. Medawar, Billingham and Leslie 
Brent induced chimerism and homograft acceptance in mice by injecting inoculating intrauterine fetuses 
with donor strain spleen cell[18]. This was ultimately successful and resulted in a Nobel Prize in 1966 for Peter 
Medawar. They later discovered that some of the immunocompetent cells from the splenic tissues “attacked” 
the lymphoid tissue of the host (Graft-Versus-Host-Disease), thereby proving the role of cellular immunity as 
first theorised by Loeb[14].
Meanwhile, Joseph Murray and his team performing the first successful kidney transplant in 1954 using as 
a donor the recipient’s identical twin bypassing the issues with immunity[19]. This generated a lot of interest 
in the field of transplantation. Joan Main and Richmond Prehn attempted to recreate Medawar’s stem cell 
inoculation. They radiated mice to allow induction of bone marrow from a donor. Murray’s team used this 
method with poor outcomes as 11 of the 12 patients who underwent kidney transplantation with total body 
irradiation died within a month[14]. The survivor maintained adequate function of his fraternal twin’s kidney 
for 20 years thereby becoming the first successful non-identical twin kidney transplantation. Jean Ham-
burger and René Küss from Paris performed 4 successful transplants using total body irradiation without 
marrow inoculation[15].
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EARLY IMMUNOSUPPRESSION
Robert Schwartz and William Dameshek discovered that 6-mercaptopurine (6-MP), which was primarily 
used for treatment of malignancies, also reduced the antibody response of rabbits to bovine albumin[14]. 
Roy Calne used 6-MP on canine kidney homografts and noted that it significantly prolonged survival[20]. 
His findings however were not replicated when 3 kidney transplant recipients treated with 6-MP died. 
Calne began a research fellowship with Joseph Murray and despite the trend of total body irradiation, pur-
sued work with 6-MP and later azathioprine[14].
In 1963, at a National Research Council conference in Washington, the preliminary results of total body 
irradiation versus immunosuppressive drugs had reached equipoise with few patients surviving beyond 1 
year. The practice of transplantation was questioned due to its poor long-term survival. Every represented 
centre demonstrated poor survival bar one. Thomas Starzl, combining azathioprine with prednisone 
achieved > 70% survival at 1-year follow up[21]. He noted that large doses of prednisone could reverse early 
rejection that occurred and this could then be tapered down. This led to the formation of 50 new trans-
plant centres in the United States alone that year[16] and remained the mainstay of immunosuppression for 
the next 20 years. Immunosuppression also brought a new pathology, opportunistic infections and malig-
nancy. Starzl himself noted that there were a high rate of bacterial, viral, fungal and protozoal infections 
found in post-mortem examination[22].
Antilymphocyte serum (ALS) was first discovered by Elie Metchnikoff in 1899. In 1961, Byron Waksman 
identified that lymphocytic depletion could suppressed delayed hypersensitivity reactions[23]. Combining 
the two concepts, Michael Woodruff demonstrated that ALS administration alongside thoracic duct drain-
age via a fistula extended skin allograft survival in rodents, a finding later replicated by Medawar[24,25]. In 
1966, Polyclonal antilymphocyte globulin (ALG) was successfully synthesized from human leukocyte in-
oculated horses and became the staple of a triple regimen alongside steroids and azathioprine[26].
HISTORY OF CARDIAC SURGERY AND TRANSPLANTATION
Unlike its other surgical counterparts, cardiac surgery was a relatively unknown subspecialty in the early 
20th century. In 1881 at the Vienna Medical Society, Theodore Billroth once proclaimed.
“No surgeon who wished to preserve the respect of his colleagues would ever attempt to suture a wound of 
the heart”[27].
The first cardiac procedure of the modern era was performed by Henry C. Dalton in St. Louis to repair a 
pericardial wound in a victim of a stabbing[28]. In 1923, Elliot Carr Cutler and Samuel A. Levine success-
fully relieved a stenotic mitral valve in a 12-year-old girl. F. John Lewis, performed the first successful re-
pair of an atrial septal defect in 1952 using hypothermia to protect the myocardium[29]. C. Walton Lillehei 
performed 45 open heart surgeries utilizing a technique called controlled cross-circulation using parents of 
the children as “pump oxygenators”[30].
The introduction of the cardiopulmonary bypass circuit revolutionised cardiac surgery. John Gibbon per-
fected the device in 1953 and subsequently perfored the successfully performed an atrial septal defect clo-
sure[31]. John Kirklin modified the pump and achieved relative success in small series of patients at the Mayo 
Clinic[32]. However it was Richard DeWall’s cardiopulmonary bypass device with a disposable bubble oxy-
genator and simple pump action that enabled the correction of cardiac conditions under direct vision[33].
The ensuing period saw numerous attempts to correct myocardial ischaemia until the Robert Hans Goetz suc-
cessful grafted the right internal mammary artery to the right coronary artery, thereby performing the first 
coronary artery bypass graft in 1960, much to the chagrin of the medical and surgical fraternity at the time[34].
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Inspired by the work of Carrel and Loeb, Frank C Mann identified 2 techniques for heterotopic cardiac 
transplantation[35]. In his experimental model, he described using either a distal or proximal end of a di-
vided carotid artery to supply blood to the aorta and assist circulation. The coronary sinus blood returned 
to the right atrium with both the vena cavae closed off and drained into the right ventricle. The pulmonary 
artery was anastomosed to the jugular vein. They noted that the pulse generated by the heart gradually 
faded with the longest lasting heart failing after 8 days.
Vladimir Demikhov, a visionary surgeon developed a mechanical device too large to be inserted entirely 
within the thorax of a dog, but it functioned as a substitute for the heart for as long as 5.5 h. Till 1946, 
intrathoracic transplantation had never been accomplished in a warm-blooded animal. The first issue en-
countered was ongoing nourishment of the heart using arterialised blood. He ligated of the aorta, venae ca-
vae, azygos, and brachiocephalic and left subclavian arteries perfused the heart with arterialised blood was 
returned to the left atrium after passing through the pulmonary circuit and delivered by the left ventricle 
into the coronaries. He used this method in around 300 experiments and maintained the heart in good 
condition for up to 4 h[36].
Despite multiple initial failures of intrathoracic transplant of the heart, one dog survived for 32 postopera-
tive days. Perhaps his greatest achievement was a series of orthotopic heart transplants that he performed 
without hypothermia or the use of a cardiopulmonary bypass machine. He performed and end-to-side 
anastomosis of the donor aorta, pulmonary artery and venae cavae to the corresponding recipient vessels 
and reattached the pulmonary veins to the recipients left atrium and closed off with a purse strings. He 
reported survival times of up to 15.5 h, thereby creating the first model of an orthotopic heart transplant 
providing the entirety of the pumping function[37]. Demikhov’s research was not published in English 
until 1962.
Interest in Frank C Mann’s work was rekindled in 1951. Marcus et al created a technique using 3 dogs, a 
donor, a recipient and a receptacle for the donor heart when disconnected from the circulation[38]. The final 
model was not to dissimilar to the cross-circulation utilized by Lillihei. This “interim parabiotic perfusion” 
was used to place the heart in the 2 previously mentioned configurations as described by Mann. In 1953, 
Marcus and associates managed to achieve a survival time of 48 h for heterotopic heart transplantation[39]. 
Wilfred Neptune and colleagues were the first to utilise hypothermia with a heart-lung block and achieved 
a survival time of 6 h in a canine model[40].
Webb, Howard and Neely produced 12 successful orthotopic heart transplants surviving as long as 7.5 h us-
ing a different method of anastomosing the pulmonary veins of the donor to recipient compared to Demik-
hov[41]. The first involvement of British cardiac surgeons occurred in 1959 when Cass and Brock described 
a series of methods for autotransplantation while including leaving the recipients atria and septal crest 
behind to avoid pulmonary vein and vena cavae anastomosis[42].
In 1960, Lower and Shumway published results of their experiments with orthotopic homotransplantations 
using an oxygenator and partial atrial preservation as described by Cass and Brock. They yielded excellent 
results with 5 of the 8 dogs experimented on surviving between 6-21 days[43]. To date, the bi-atrial anasto-
mosis is still noted as the Shumway Technique. 
Shumway paid meticulous attention to surgical technique and myocardial protection using isotonic saline at 
4 °C. In addition they introduced the concept of assistance time whereby the recipient dogs were left on the 
cardiopulmonary bypass for a short period of time to ease the heart into assuming the circulatory load[44].
Shumway’s group also described initial issues such as the incidence of complete atrioventricular block. On 
learning lessons from rejection in renal transplant patients, Reemtsa et al attempted to use methotrexate 
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for heterotopic heart transplantation in 21 canines, and prolonged survival up to 26 post-operative days[45]. 
Blumenstock mimicked the findings of Reemtsma’s group with one canine in their cohort surviving for up 
to 42 days in 1963[46].
The first ethical dilemma faced by the fraternity was the concept of the donor as “the definition of irrevers-
ible coma” was only established in 1968 by an Ad Hoc Committee of Harvard Medical School on Brain 
Death[47]. The likelihood of a potential donor dying at exactly the same time as a recipient needing a heart 
was minute and a decision was made that the team would not halt ventilation of the patient in January 
1964, but instead would utilise a chimpanzee as a donor[48]. A patient presented with a large thrombus that 
had embolised to the left side of the heart and placed on mechanical coronary perfusion. The chimpanzee 
heart was explanted and implanted into the patient. Despite initially beating well, it became apparent that 
the heart was not able to support the larger volume of a human circulation and the patient died within an 
hour of weaning from cardiopulmonary bypass.
Dr. Christiaan Barnard had worked alongside Shumway in Minnesota. He had also performed the first 
successful kidney transplant in South Africa to understand transplant immunology and geared for a heart 
transplantation. On 14th September 1967, Louis Washkansky was admitted in the Groote Schuur Hospital 
in Cape Town, South Africa. Dr. Velva Schrire (Chief Cardiologist) recommended Washkansky as the ap-
propriate case for transplant. On 2nd December 1967, a 24-year-old female, Denise Ann Darvall was pro-
nounced dead after sustaining a massive cerebral injury following a collision. Both patients were brought 
to theaters A and B where and mutual consent was obtained[49].
“If you can’t save my daughter, you must try and save this man.” Edward Darvall (Denise’s Father).
On 3rd December 1967, Dr. Christiaaan Barnard performed the first successful human-to-human or-
thotopic heart transplantation. Her heart was taken via the Shumway technique with the heart cooled to 
10 °C. He used a combination of local irradiation, azathioprine, prednisone, and actinomycin C as his im-
munosuppression regime. The post-operative course of the patient was very promising, he contracted Pseu-
domonas pneumonia and died on the 18th post-operative day[50].
Dr. Adrian Kantrowitz and his team performed the 2nd heart transplant (the first in a paediatric patient) 
in Brooklyn. Kantrowitz was already well known for designing the first intra-aortic balloon pump and 
had conducted considerable laboratory experiments in puppy hearts believing that the immune system of 
a younger heart may offer less allogenic resistance. On 6th December 1967, He transplanted a anenceph-
alic donor heart into a 3 week-old patient diagnosed with tricuspid atresia. He performed the operation in 
hypothermic conditions under circulatory arrest. Despite initial recovery into sinus rhythm, the recipient 
developed irreversible acidosis and died[51].
Norman Shumway and his team performed their first heart transplant a month after Kantrowitz. The re-
cipient developed chronic and progressive heart failure after “post-viral myocardial fibrosis” and coronary 
artery disease. The procedure was complicated by size mismatch with the donor heart being much smaller 
than the recipient’s. The recipient received a combination of methylprednisolone and azathioprine preop-
eratively and post-operatively with the addition of prednisolone. However, the patient did not succumb to 
rejection. Shumway noted that in the initial post-operative period the patient was mildly hypotensive and 
oliguric into the second postoperative day despite administration of isoproterenol and temporary digitali-
zation. The patient developed a consumptive coagulopathy before succumbing to multiorgan dysfunction 
and bronchopneumonia[52].
Across the Atlantic, Dr. Donald Ross, who trained under Lord Russell Brock, performed the first heart 
transplant in the United Kingdom. The patient, a 45-year-old man, survived for 46 days before succumbing 
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to infection. He performed 2 more unsuccessful transplants before a moratorium was declared[53].
Denton Cooley’s group reported moderate success early on at Baylor with 7 of 10 patients surviving 
4.5 months[54]. To reduce the risk of rejection, they used blood-group compatibility, lymphocyte crossmatch 
studies (histocompatibility) as described by Dr. Paul Terasaki, and developed a matching system to predict 
the likelihood of a good outcome post-transplant[55]. They also administered anti-lymphocyte globulin in 
addition to the other anti-rejection medications.
EARLY ISSUES WITH HEART TRANSPLANTATION
Within a year of the Barnard’s feat, 102 heart transplantations were performed internationally[56]. Shumway 
famously quipped “Suddenly heart transplants were being done in places where one would hesitate to have 
his atrial septal defect closed”.
The early promise of heart transplantation however soon diminished asthe number of transplants rapidly 
fell from 100 (1968) to 18 (1970), with many inexperienced units abandoning the procedure. Kantrowitz, 
who was on the review panel for the National Institute of Health agreed to support Shumway and his unit 
in their ongoing research[57]. In 1971, they identified several identifiers of acute rejection[58]:
(1) Electrocardiographic findings: i. Increased QRS voltage; ii. Arrhythmia; iii. Right axis deviation; iv. 
ST-T wave changes;
(2) Clinical Findings: i. Appearance of gallop rhythm; ii. Decreased precordial activity; iii. Hypotension;
(3) Echocardiography findings: i. Increased thickness of left ventricular wall; ii. Increased right ventricular 
diameter.
Using the above-mentioned criteria, they successfully treated 57 of 60 patients with methylprednisolone, 
actinomycin D and ALG. As the experience of long-term survival in heart transplants increased, Shumway 
noted a condition he titled “chronic rejection”[59]. It manifested as diffuse allograft vasculopathy and led to 
episodes of sick sinus syndrome or myocardial infarction, usually proving fatal.
In 1962, Dr. Souji Konno developed the catheter-type endomyocardial biopsy (EMB) allowing samples 
of myocardium of patients suspected of having intrinsic musculature abnormality to be taken using a 
bioptome inserted via a peripheral vein or arterial cutdown[60]. It was initially developed for diagnoses of 
cardiomyopathies as opposed to limited thoracotomy approaches. The biotome usually provided samples 
containing endocardium and myocardium, usually sufficient for microscopic examination.
In 1971, a young cardiothoracic surgeon, Dr. Philip Caves undertook a British American Research Fellow-
ship to Stanford to work with Shumway. While here, he worked with instrument maker, Werner Schulz 
to create the Stanford-Caves Schulz bioptome which transformed the management of heart transplant pa-
tients. There were 2 Stanford bioptomes that differed in size and length. The longer and thinner bioptome 
was used for left ventricular biopsy and the shorter and thicker one for right ventricular biopsy[61,62]. The 
samples obtained were between 1-3 mm in diameter. He noted that changes seen in endomyocardial speci-
mens matched those seen in grafts at post-mortem examinations. The samples taken from the endomyocar-
dial surface were also free of post-operative inflammatory changes that complicated sub-epicardial samples 
taken during thoracotomy. Finally, he noted that the pathologic changes of cardiac allograft rejection were 
more prominent in the endomyocardial surface (as the graft came in direct contact with the host’s circula-
tion). Philip Caves also worked with Margaret Billingham who was a pathologist at Stanford. In 1974, they 
developed a standardised histological scale to pathologically grade the severity of cardiac rejection based 
on the extent of infiltrates[63]. This was incorporated into routine practice and significantly improved the 
survival of heart transplant recipients at Stanford.
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IMMUNOSUPPRESSION IN HEART TRANSPLANTATION
Ciclosporin
Another notable feat in transplantation during this era was the discovery of Ciclosporin A. In 1976, J.F 
Borel reported the immunosuppressive effects of a fungal metabolite (Tolypocladium inflatum) isolated 
from Swiss soil samples. He noted that skin graft rejection in mice and graft-versus-host disease in mice 
and rats were considerably delayed by cycloporin A. He also noted that it had a direct antilymphocytic ef-
fect by targeting an early stage of mitogenic triggering of the immunocompetent lymphoid cell and lacked 
the myelosuppressive effects of cytostatic drugs used at the time[64]. Roy Calne, who previously worked on 
azathioprine, conducted in vivo immunosuppression with ciclosporin A on porcine cardiac allografts. His 
group stated that “Ciclosporin A is more effective in suppressing rejection than any other drug that we 
have used in pigs with orthotopic cardiac allografts”[65].
Terence English, a South African born surgeon who previously worked with Lord Russell Brock and Don-
ald Ross, nearly abandoned medicine to be a mining engineer. He visited Stanford on advice of his friend 
Philip Caves in 1973[66]. He was truly impressed with the outcomes of heart transplant recipients at the 
unit. In 1978, Terence English, sought approval from the Transplant Advisory Panel of the Department of 
Health but was informed that there were no funds for a transplant programme[67]. Given the moratorium, 
the panel were not keen on “one-off” operations. He duly persisted but his initial attempt was unsuccessful 
as the donor had arrested prior to implantation and sustained an irreversible brain injury. He persevered 
and in July 1979, performed the first successful heart transplant in the United Kingdom. The recipient, 
Keith Castle lived for 5 and a half years[68].
“He subsequently became the best possible advertisement for cardiac transplantation except for his inabil-
ity to give up smoking” Sir Terence English on Keith Castle[68].
Although initial reports on Ciclosporin were favourable, the improvements came with a price. Ciclosporin 
was nephrotoxic when used over a long period[69]. Other side effects include hypertension, hepatotoxicity, 
gingival hyperplasia, hypertrichosis, involuntary tremor, and an increased risk of malignancy[70]. With the 
improvements in survival after the initial transplantation, the recipients were at risk of nephrotoxicity and 
morbidities associated with immunosuppression primarily infections. These drawbacks however did not 
offset positive impact Ciclosporin offered over previous methods. Immunosuppression formed the initial 
challenges in cardiac transplantation with suboptimal immunosuppressive regimens either causing al-
lograft rejection or infectious complications from over-immunosuppression.
A European Multicentre trial evaluating renal graft survival at 1-year showed that Ciclosporin alone as a 
first-line immunosuppressive agent was more effective than with azathioprine and steroids[71]. Stanford’s 
group meanwhile reported 1 and 5-year survival rates of 83% and 55%, respectively using a 3-drug protocol 
of Ciclosporin A, azathioprine, and prednisone[72].
Tacrolimus
Tacrolimus (Tradename: Prograf®, Astellas Pharma US, Inc. Northbrook, IL) a calcineurin inhibitor like 
Ciclosporin was discovered from a soil sample from the foot of Mount Tsukuba in Tokyo in 1984. It was 
cultured from an actinobacter, Streptomyces tsukubaensis[73]. It suppresses interleukin-2 production associ-
ated with T-cell activation, thus inhibiting the differentiation and proliferation of cytotoxic T cells. Thomas 
Starzl once again led research into safety and efficacy of Tacrolimus at University of Pittsburgh Medical 
School[74]. Tacrolimus had a more limited adverse effect profile and comparative studies suggest superiority 
over Ciclosporin in preventing allograft rejection while causing less antibody suppression[75,76]. The phar-
macokinetics were far more predictable than for micro-emulsion Ciclosporin[77].
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Numerous randomized controlled trials comparing tacrolimus to Ciclosporin have been done. Two mul-
ticentre studies comparing tacrolimus to oil-based Ciclosporin (Tradename: Sandimmune® Oral Solu-
tion, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) showed no significant difference 
between the groups at 12 months. Graft survival, renal function and infection rates were not significantly 
different between the groups although more patients in the Ciclosporin group developed hypertension and 
hypercholesterolaemia[78,79].
A micro-emulsion formulation of Ciclosporin (Tradename: Neoral® Oral Solution, Novartis Pharmaceuticals 
Corporation, East Hanover, New Jersey 07936) was developed and was shown to have a better bioavail-
ability profile with more predictable pharmacokinetics compared to the oil-based preparations[80]. A multi-
center, randomized study of both preparations of Ciclosporin revealed fewer episodes of rejection requiring 
antilymphocyte antibodies and fewer study discontinuations for treatment failures in the micro-emulsion 
based Ciclosporin cohort of patients compared to those treated with oil-based Ciclosporin without any ad-
verse events[81].
When compared to tacrolimus, micro-emulsion based Ciclosporin (alongside cytolytic induction) and a 
tapered steroid regime showed equivalent patient and graft survival at 19 months. However, there was an 
increased incidence of biopsy proven acute rejection in the Ciclosporin group at 6 months. Tacrolimus was 
associated with a higher incidence of new-onset diabetes mellitus, lower rates of post-transplant hyperten-
sion and lower incidences of dyslipidaemia[82]. Similar findings were noted in another trial without cyto-
lytic induction[83].
Mycophenolate mofetil
Another agent that is commonly used is [mycophenolate mofetil (MMF); CellCept, Roche Laboratories, 
Nutley, NJ]. It is an effective anti-proliferative agent that improves rejection and survival when used as part 
of combination therapy. Its active metabolite, mycophenolic acid, is a non-competitive inhibitor of inosine 
monophosphate dehydrogenase in the de novo pathway for purine synthesis[84]. Therefore, MMF has some 
selectivity for lymphocytes over other cell types as lymphocytes rely on this pathway for DNA replication 
and proliferation. Studies have shown that heart transplant patients receiving MMF therapy had lower lev-
els of C-reactive protein, circulating B lymphocytes, activated T lymphocytes and natural killer (NK) cells 
compared to patients receiving azathioprine[85].
Mechanistic target of rapamycin inhibitors
Everolimus (Tradename: Certican, Novartis Pharma Schweiz AG, Bern, Switzerland) and Sirolimus (Trade-
name: Rapamune, Wyeth Europa Ltd., Maidenhead, UK) are mechanistic target of rapamycin inhibitors[86]. 
They work by inhibiting proliferation signals by suppressing the cytokine-driven T-lymphocyte prolifera-
tion, resulting in an arrest of the cell cycle. Unlike the calcineurin inhibitors, they demonstrate little or no 
nephrotoxic side effects. Recent studies have even shown a reduction in the incidence of chronic allograft 
vasculopathy(CAV) with Everolimus as measured by IVUS among heart-transplant recipients after 1 
year[87,88]. Sirolimus however is linked to an increase in total cholesterol and triglyceride levels[89,90]. Everoli-
mus on the other hand, is linked with an increase in total cholesterol levels, without increased triglyceride 
levels, but a significant increase in HDL which may explain its attenuation of CAV[91].
Cytolytic induction therapy
Cytolytic Induction therapy comprises of immunosuppressive drugs that have been introduced into clini-
cal transplantation directed against human lymphoid cells. Several different forms of cytolytic induction 
therapy have been used as identified in Table 1. 
In heart transplantation especially, kidney dysfunction has been demonstrated to be risk factors for early 
death[93,94]. Cytolytic induction allows post-operative renal recovery from a pre-renal aetiology without the 
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negative impact of high nephrotoxic ciclosporinCiclosporin/tacrolimus levels. It effectively allows bridg-
ing of immunosuppression until a steady state is reached for the regular immunosuppression medications. 
Most centres use a combination of the abovementioned immunosuppressants to achieve adequate im-
munosuppression. In 2006, Kobashigawa led a trial comparing 3 different immunosuppression regimes, 
micro-emulsion Ciclosporin with MMF, tacrolimus with MMF or tacrolimus with sirolimus[95].
The 343 heart transplant recipients in this trial were randomized to receive corticosteroids and on of the 
mentioned regimes. Cytolytic induction therapy was used for up to 5 days. The primary endpoint of moder-
ate rejection or haemodynamic compromise rejection requiring treatment showed no significant difference 
between the three groups at 6 months and 1 year. The probability of treated rejection was significantly lower 
in both the tacrolimus groups compared with the micro-emulsion Ciclosporin/mycophenolate mofetil group. 
The tacrolimus/sirolimus group had more fungal infections and more impaired wound healing. 
On the other hand, recent trials involving combinations with everolimus have shown promising results 
including reduced cytomegalovirus infections[96], reduced cutaneous cancer incidence[97], and CAV attenua-
tion effects[98].
CURRENT STATUS OF HEART TRANSPLANTATION
Heart transplantation is considered to be the “gold-standard treatment” for refractory advanced heart 
failure in carefully selected patients[99-101]. A major limiting factor of transplantation is the emerging gap 
between the number of donors (available grafts) and the number of patients on the waiting list. This issue 
is apparent even in the neighbouring France[102]. The utilization of marginal donors or expanded-criteria 
donors has steadily increased over the decades. Part of the decision-making process currently between 
physician, surgeon and patient includes discussing the potential options available. Currently, the choices 
include continued medical therapy (5% to 10% weekly mortality risk), mechanical circulatory support (10% 
to 15% operative risk), or a transplant which may or may not include a clause for marginal organs.
The “Standard Donor” or “Traditional Criteria” for a donor as suggested by Copeland[103] is as follows: (1) 
age < 50 years; (2) echocardiogram showing no important segmental abnormalities or global hypokinesis, 
ejection fraction greater than 50%, and normal valves; (3) inotropes less than 15 µg/kg/min of dopamine; 
(4) donor to recipient weight ratio 1.5 to 0.7; (5) cold ischemic time less than 4 h; (6) no donor infection; (7) 
negative serology for hepatitis B, hepatitis C, and human immunodeficiency Virus; and (8) normal electro-
cardiogram or minor ST-T wave abnormalities, with no conduction system disease.
The rising number of patients listed for heart transplantation has resulted in an increased number of do-
nors from beyond the “standard criteria” pool as a result of the undersupply of available organs. “Marginal 
Donors” as they are termed would, under conventional transplant guidelines, be declined as potential or-
gan donors[104]. Median waiting times in the UK for hearts on the non-urgent list is currently 1280 days and 
26 days for the urgently listed[105] [Figure 1].
Substance Origin Dosages applied Routes investigated Monoclonal/polyclonal
Antilymphocyte-Globulin ATGAM Horse Various 7-14 days IM Polyclonal
Antithymocyte-Globulin Bieber-ATG Tecelac Rabbit 1, 5-3 mg/kg per day 
1-10 days
IM/IV Polyclonal
OKT III antibody Mouse 5-10 mg/day
4-14 days
IV Monoclonal
BMA 031 antibody Mouse Experimental IV Monoclonal
Anti-LFA antibody Synthetic Experimental IV Monoclonal
Table 1. Different types of cytolytic induction therapy available (adapted with permission from Wahlers[92])
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Forays into xenotransplantation as a potential pool of organs to solve the problem of donor-organ supply 
were also touted but to date, these remain in the experimental phase[106].
The decision to accept a marginal donor organ is made on a recipient focused individualized basis rather 
than specific values, parameters or conditions [Figure 2].
The number of “standard donors” for kidney transplants were first notably reduced after the implementa-
tion of the compulsory wearing of seat belts in the United Kingdom which was approved by parliament 
in 1982 and became law on 1 February 1983[107]. Other legislations include zero-tolerance drinking-and-
driving law resulting in fewer traffic accidents with fatal victims[108]. During this time period the United 
Kingdom Transplant Support Service Authority demonstrated a 12% increase in the number of cardiac do-
nors aged greater than 41 years between 1988 and 1995[109]. The initial reluctance to use organs from older 
donors especially the heart was due to longstanding dogma that older hearts were thought to more suscep-
tible to the catecholamine flood that accompanies brain death[110]. Internationally, gun crime has also been 
closely associated with donor organ availability. Studies in Brazil have shown a direct correlation between 
urban violence and gun crime to organ donors[111,112].
Initial studies exploring the extended age criteria showed no significant difference in terms of left ventricu-
lar function and the incidence of infection and rejection[109,113]. The risk of dying on the waiting list out-
weighed that of receiving an organ from an older donor[114].
Figure 1. Deceased donor heart programme in the UK, 1 April 2007 - 31 March 2017, number of donors, transplants and patients on the 
active transplant list at 31 March
Singh et al. Vessel Plus 2018;2:33  I  http://dx.doi.org/10.20517/2574-1209.2018.28                                                    Page 11 of 17
Some surgeons also opted to accept hearts with mild-to-moderate mitral or tricuspid insufficiency or 
secundum-type atrial septal defects as these could be repaired immediately or post-operatively with 
good results[115].
As the understanding of myocardial protection improved, the use of mildly hypertrophic left ventricles 
with short ischaemic times were also proposed with the caveat that there were no ECG changes[116].
Patients with underlying malignancies were previously never considered donor candidates. However, the 
risk of metastasis from a primary intracranial tumour is low. A German study in one of the earliest studies 
evaluating the outcomes of recipients receiving organs from donors with intracranial malignancies showed 
good follow up outcomes of more than 5 years[117].
Transplantation also requires commitment from the patients and health care providers as it involves a 
long-term programme of treatment including pharmacological immunosuppression and regular surveil-
lance[118]. Clinical decisions therefore should consider a patient’s ability to adhere to the demands of ongo-
ing treatment. Alternatives to transplantation include the use of Ventricular Assist Devices (VADs). These 
are however limited in the National Health Service (NHS) due to the limited health care funding. In North 
America, the Food and Drug Administration recently approved VADs as destination therapy[119]. In its cur-
rent form, heart transplantation confers a significant survival advantage with a 1-year survival of 84.5% 
and a 5-year survival of 72.5% which is significantly improved as compared to the 76.9% 1-year survival 
and 62.7% 5-year survival in the 1980s[120,121].
PRIMARY DIAGNOSTIC INDICATIONS FOR TRANSPLANT
The most frequent indications for heart transplantation in adults are chronic heart failure second-
ary to dilated cardiomyopathy or ischaemic heart disease[118]. There is also a significant number of 
patients(approximately 3%) with adult congenital heart disease who present with advanced heart failure 
in adulthood[122]. These patients are slightly more complex to manage both surgically (due to the abnormal 
anatomy, complex adhesions) and medically (due to human leucocyte antigen sensitisation, potentially 
elevated pulmonary vascular resistance secondary to univentricular circulations and erythrocytosis sec-
ondary to cyanosis)[118,122]. Coronary artery disease is the most important contributor to heart failure with 
a population-attributable risk of 65% in men and 48% in women[123]. Most of the patients however can be 
classified into ischaemic or non-ischaemic cardiomyopathies.
Figure 2. Timeline of events where modifications of “Standard criteria” toward more marginal donors were implemented
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